Works matching IS 03407004 AND DT 2021 AND VI 70 AND IP 10

Results: 28

Correction to: CD163+CD14+ macrophages, a potential immune biomarker for malignant pleural effusion.

Published in:

2021

By:

Wang, Fei;
Yang, Li;
Gao, Qun;
Huang, Lan;
Wang, Liping;
Wang, Jing;
Wang, Shengdian;
Zhang, Bin;
Zhang, Yi

Publication type:

Correction Notice

Multiplexed single-cell pathology reveals the association of CD8 T-cell heterogeneity with prognostic outcomes in renal cell carcinoma.

Published in:

Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 3001, doi. 10.1007/s00262-021-03006-2

By:

Murakami, Tetsushi;
Tanaka, Nobuyuki;
Takamatsu, Kimiharu;
Hakozaki, Kyohei;
Fukumoto, Keishiro;
Masuda, Tsukasa;
Mikami, Shuji;
Shinojima, Toshiaki;
Kakimi, Kazuhiro;
Tsunoda, Tatsuhiko;
Sawada, Kazuaki;
Imamura, Takeshi;
Mizuno, Ryuichi;
Oya, Mototsugu

Publication type:

Article

Correction to: Cancer testis antigen Cyclin A1 harbors several HLA‑A*02:01‑restricted T cell epitopes, which are presented and recognized in vivo.

Published in:

2021

By:

Teck, Anja Tatjana;
Urban, Sabrina;
Quass, Petra;
Nelde, Annika;
Schuster, Heiko;
Letsch, Anne;
Busse, Antonia;
Walz, Juliane Sarah;
Keilholz, Ulrich;
Ochsenreither, Sebastian

Publication type:

Correction Notice

Phase I/II clinical trial of adoptive cell transfer of sorted specific T cells for metastatic melanoma patients.

Published in:

Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 3015, doi. 10.1007/s00262-021-02961-0

By:

Dréno, Brigitte;
Khammari, Amir;
Fortun, Agnès;
Vignard, Virginie;
Saiagh, Soraya;
Beauvais, Tiffany;
Jouand, Nicolas;
Bercegay, Sylvain;
Simon, Sylvain;
Lang, François;
Labarrière, Nathalie

Publication type:

Article

Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports.

Published in:

Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 3041, doi. 10.1007/s00262-021-02938-z

By:

Inno, Alessandro;
Maurea, Nicola;
Metro, Giulio;
Carbone, Andreina;
Russo, Antonio;
Gori, Stefania

Publication type:

Article

Tumor morphology and location associate with immune cell composition in pleomorphic sarcoma.

Published in:

Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 3031, doi. 10.1007/s00262-021-02935-2

By:

Wustrack, Rosanna L.;
Shao, Evans;
Sheridan, Joey;
Zimel, Melissa;
Cho, Soo-Jin;
Horvai, Andrew E.;
Luong, Diamond;
Kwek, Serena S.;
Fong, Lawrence;
Okimoto, Ross A.

Publication type:

Article

Correction to: Effect of chemoradiotherapy on the proportion of circulating lymphocyte subsets in patients with limited‑stage small cell lung cancer.

Published in:

2021

By:

Chen, Yamei;
Jin, Ying;
Hu, Xiao;
Chen, Ming

Publication type:

Correction Notice

Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors.

Published in:

Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2991, doi. 10.1007/s00262-021-02910-x

By:

Do, Khanh T.;
Manuszak, Claire;
Thrash, Emily;
Giobbie-Hurder, Anita;
Hu, Jiani;
Kelland, Sarah;
Powers, Allison;
de Jonge, Adrienne;
Shapiro, Geoffrey I.;
Severgnini, Mariano

Publication type:

Article

Tumor immune microenvironment in brain metastases from gynecologic malignancies.

Published in:

Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2951, doi. 10.1007/s00262-021-02909-4

By:

Gill, Corey M.;
D'Andrea, Megan R.;
Tomita, Shannon;
Suhner, Jessa;
Umphlett, Melissa;
Zakashansky, Konstantin;
Blank, Stephanie V.;
Tsankova, Nadejda;
Shrivastava, Raj K.;
Fowkes, Mary;
Kolev, Valentin

Publication type:

Article

Effect of chemoradiotherapy on the proportion of circulating lymphocyte subsets in patients with limited-stage small cell lung cancer.

Published in:

Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2867, doi. 10.1007/s00262-021-02902-x

By:

Chen, Yamei;
Jin, Ying;
Hu, Xiao;
Chen, Ming

Publication type:

Article

Natural killer cells efficiently target multiple myeloma clonogenic tumor cells.

Published in:

Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2911, doi. 10.1007/s00262-021-02901-y

By:

Leivas, Alejandra;
Risueño, Ruth M.;
Guzmán, Alma;
Sánchez-Vega, Laura;
Pérez, Manuel;
Megías, Diego;
Fernández, Lucía;
Alonso, Rafael;
Pérez-Martínez, Antonio;
Rapado, Inmaculada;
Martínez-López, Joaquín

Publication type:

Article

Clinical significance of peripheral TCR and BCR repertoire diversity in EGFR/ALK wild-type NSCLC treated with anti-PD-1 antibody.

Published in:

Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2881, doi. 10.1007/s00262-021-02900-z

By:

Nakahara, Yoshiro;
Matsutani, Takaji;
Igarashi, Yuka;
Matsuo, Norikazu;
Himuro, Hidetomo;
Saito, Haruhiro;
Yamada, Kouzo;
Murotani, Kenta;
Hoshino, Tomoaki;
Azuma, Koichi;
Sasada, Tetsuro

Publication type:

Article

The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte.

Published in:

Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2893, doi. 10.1007/s00262-021-02898-4

By:

Han, Baojuan;
Dong, Lina;
Zhou, Jing;
Yang, Yan;
Guo, Jiaxun;
Xuan, Qijia;
Gao, Kun;
Xu, Zhenguo;
Lei, Wanting;
Wang, Jingxuan;
Zhang, Qingyuan

Publication type:

Article

The impact of selenium on regulatory T cell frequency and immune checkpoint receptor expression in patients with diffuse large B cell lymphoma (DLBCL).

Published in:

Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2961, doi. 10.1007/s00262-021-02889-5

By:

Dehghani, Mehdi;
Shokrgozar, Negin;
Ramzi, Mani;
Kalani, Mehdi;
Golmoghaddam, Hossein;
Arandi, Nargess

Publication type:

Article

Modeling human tumor-immune environments in vivo for the preclinical assessment of immunotherapies.

Published in:

Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2737, doi. 10.1007/s00262-021-02897-5

By:

Bareham, Bethany;
Georgakopoulos, Nikitas;
Matas-Céspedes, Alba;
Curran, Michelle;
Saeb-Parsy, Kourosh

Publication type:

Article

Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy.

Published in:

Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2851, doi. 10.1007/s00262-021-02895-7

By:

Wenthe, Jessica;
Naseri, Sedigheh;
Labani-Motlagh, Alireza;
Enblad, Gunilla;
Wikström, Kristina I.;
Eriksson, Emma;
Loskog, Angelica;
Lövgren, Tanja

Publication type:

Article

Polymorphism of formyl peptide receptor 1 (FPR1) reduces the therapeutic efficiency and antitumor immunity after neoadjuvant chemoradiotherapy (CCRT) treatment in locally advanced rectal cancer.

Published in:

Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2937, doi. 10.1007/s00262-021-02894-8

By:

Chiang, Shu-Fen;
Huang, Kevin Chih-Yang;
Chen, William Tzu-Liang;
Chen, Tsung-Wei;
Ke, Tao-Wei;
Chao, K. S. Clifford

Publication type:

Article

Simultaneously target of normal and stem cells-like gastric cancer cells via cisplatin and anti-CD133 CAR-T combination therapy.

Published in:

Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2795, doi. 10.1007/s00262-021-02891-x

By:

Han, Yang;
Sun, Bo;
Cai, Hong;
Xuan, Yi

Publication type:

Article

Prognostic value of PD-L1 combined positive score in patients with upper tract urothelial carcinoma.

Published in:

Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2981, doi. 10.1007/s00262-021-02890-y

By:

Chen, Chien-Hsu;
Tsai, Mu-Yao;
Chiang, Ping-Chia;
Sung, Ming-Tse;
Luo, Hao-Lun;
Suen, Jau-Ling;
Tsai, Eing-Mei;
Chiang, Po-Hui

Publication type:

Article

Identified lung adenocarcinoma metabolic phenotypes and their association with tumor immune microenvironment.

Published in:

Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2835, doi. 10.1007/s00262-021-02896-6

By:

Wu, Xian-Ning;
Su, Dan;
Mei, Yi-De;
Xu, Mei-Qing;
Zhang, Hao;
Wang, Ze-Yu;
Li, Li-Ling;
Peng, Li;
Jiang, Jun-Yi;
Yang, Jia-Yi;
Li, Dong-Jie;
Cao, Hui;
Xia, Zhi-Wei;
Zeng, Wen-Jing;
Cheng, Quan;
Zhang, Nan

Publication type:

Article

Sarcopenia and the risk of adverse events in patients treated with immune checkpoint inhibitors: a systematic review.

Published in:

Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2771, doi. 10.1007/s00262-021-02888-6

By:

Guzman-Prado, Yuli;
Ben Shimol, Jennifer;
Samson, Ondrej

Publication type:

Article

Brief in vitro IL-12 conditioning of CD8 + T Cells for anticancer adoptive T cell therapy.

Published in:

Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2751, doi. 10.1007/s00262-021-02887-7

By:

Salem, Mohamed Labib;
Salman, Samar;
Barnawi, Ibrahim O.

Publication type:

Article

TIGIT promotes CD8+T cells exhaustion and predicts poor prognosis of colorectal cancer.

Published in:

Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2781, doi. 10.1007/s00262-021-02886-8

By:

Liang, Rongpu;
Zhu, Xudong;
Lan, Tianyun;
Ding, Dongbing;
Zheng, Zongheng;
Chen, Tufeng;
Huang, Yong;
Liu, Jianpei;
Yang, Xiaofeng;
Shao, Jun;
Wei, Hongbo;
Wei, Bo

Publication type:

Article

Combining UBR5 and CD163+ tumor-associated macrophages better predicts prognosis of clear cell renal cell carcinoma patients.

Published in:

Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2925, doi. 10.1007/s00262-021-02885-9

By:

Wang, Chao;
Hong, TianYu;
Wang, Yuning;
Peng, Guang;
Yu, Yongwei;
Zhang, Jing;
Zhuo, Dong;
Zheng, Jingcun;
Ma, Xiaojing;
Cui, Xingang

Publication type:

Article

Sex-specific hormone changes during immunotherapy and its influence on survival in metastatic renal cell carcinoma.

Published in:

Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2805, doi. 10.1007/s00262-021-02882-y

By:

Tulchiner, Gennadi;
Pichler, Renate;
Ulmer, Hanno;
Staudacher, Nina;
Lindner, Andrea Katharina;
Brunner, Andrea;
Zelger, Bettina;
Steinkohl, Fabian;
Aigner, Friedrich;
Horninger, Wolfgang;
Thurnher, Martin

Publication type:

Article

Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events.

Published in:

Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2761, doi. 10.1007/s00262-021-02880-0

By:

Nashed, Andrew;
Zhang, Shijun;
Chiang, Chien-Wei;
Zitu, M.;
Otterson, Gregory A.;
Presley, Carolyn J.;
Kendra, Kari;
Patel, Sandip H.;
Johns, Andrew;
Li, Mingjia;
Grogan, Madison;
Lopez, Gabrielle;
Owen, Dwight H.;
Li, Lang

Publication type:

Article

Potentially functional variants of ERAP1, PSMF1 and NCF2 in the MHC-I-related pathway predict non-small cell lung cancer survival.

Published in:

Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2819, doi. 10.1007/s00262-021-02877-9

By:

Yang, Sen;
Tang, Dongfang;
Zhao, Yu Chen;
Liu, Hongliang;
Luo, Sheng;
Stinchcombe, Thomas E.;
Glass, Carolyn;
Su, Li;
Shen, Sipeng;
Christiani, David C.;
Wang, Qiming;
Wei, Qingyi

Publication type:

Article

Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting.

Published in:

Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2971, doi. 10.1007/s00262-021-02852-4

By:

Wu, Zhaozhen;
Tao, Haitao;
Zhang, Sujie;
Wang, Xiao;
Ma, Junxun;
Li, Ruixin;
Liu, Zhefeng;
Wang, Jinliang;
Cui, Pengfei;
Chen, Shixue;
Di, Huang;
Huang, Ziwei;
Zheng, Xuan;
Hu, Yi

Publication type:

Article

Works matching IS 03407004 AND DT 2021 AND VI 70 AND IP 10

Correction to: CD163+CD14+ macrophages, a potential immune biomarker for malignant pleural effusion.

Multiplexed single-cell pathology reveals the association of CD8 T-cell heterogeneity with prognostic outcomes in renal cell carcinoma.

Correction to: Cancer testis antigen Cyclin A1 harbors several HLA‑A*02:01‑restricted T cell epitopes, which are presented and recognized in vivo.

Phase I/II clinical trial of adoptive cell transfer of sorted specific T cells for metastatic melanoma patients.

Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports.

Tumor morphology and location associate with immune cell composition in pleomorphic sarcoma.

Correction to: Effect of chemoradiotherapy on the proportion of circulating lymphocyte subsets in patients with limited‑stage small cell lung cancer.

Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors.

Tumor immune microenvironment in brain metastases from gynecologic malignancies.

Effect of chemoradiotherapy on the proportion of circulating lymphocyte subsets in patients with limited-stage small cell lung cancer.

Natural killer cells efficiently target multiple myeloma clonogenic tumor cells.

Clinical significance of peripheral TCR and BCR repertoire diversity in EGFR/ALK wild-type NSCLC treated with anti-PD-1 antibody.

The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte.

The impact of selenium on regulatory T cell frequency and immune checkpoint receptor expression in patients with diffuse large B cell lymphoma (DLBCL).

Modeling human tumor-immune environments in vivo for the preclinical assessment of immunotherapies.

Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy.

Polymorphism of formyl peptide receptor 1 (FPR1) reduces the therapeutic efficiency and antitumor immunity after neoadjuvant chemoradiotherapy (CCRT) treatment in locally advanced rectal cancer.

Simultaneously target of normal and stem cells-like gastric cancer cells via cisplatin and anti-CD133 CAR-T combination therapy.

Prognostic value of PD-L1 combined positive score in patients with upper tract urothelial carcinoma.

Identified lung adenocarcinoma metabolic phenotypes and their association with tumor immune microenvironment.

Sarcopenia and the risk of adverse events in patients treated with immune checkpoint inhibitors: a systematic review.

Brief in vitro IL-12 conditioning of CD8 <sup>+ </sup>T Cells for anticancer adoptive T cell therapy.

TIGIT promotes CD8<sup>+</sup>T cells exhaustion and predicts poor prognosis of colorectal cancer.

Combining UBR5 and CD163<sup>+</sup> tumor-associated macrophages better predicts prognosis of clear cell renal cell carcinoma patients.

Sex-specific hormone changes during immunotherapy and its influence on survival in metastatic renal cell carcinoma.

Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events.

Potentially functional variants of ERAP1, PSMF1 and NCF2 in the MHC-I-related pathway predict non-small cell lung cancer survival.

Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting.